您现在的位置： 首页   -  产品中心   -  免疫学   -   抗体
Biotinylated ROR1 Fc&Avi Tag Protein, Human

Biotinylated ROR1 Fc&Avi Tag Protein, Human

货号: UA010830
价格: 2450
规格: 25μg
介绍: -
其他: -
产品规格

  • 物种

    Human

  • 分子别名

    Inactive tyrosine-protein kinase transmembrane receptor ROR1, NTRKR1, ROR1, Receptor Tyrosine Kinase Like Orphan Receptor 1, Neurotrophic Tyrosine Kinase, Receptor-Related 1

  • Accession

    Q01973-1

  • 表达序列

    Gln30-Glu403, with C-terminal hIgG1 Fc and Avitag

  • 表达宿主

    HEK293

  • 分子量

    90-95kDa (Reducing)

  • 纯度

    ＞95% by SDS-PAGE

  • 内毒素含量

    <1EU/μg

  • 标记

    Biotin

  • 标签

    Human Fc Tag, Avi Tag

  • 性状

    Lyophilized Powder

  • 缓冲体系

    PBS, pH7.4.

  • 溶解方法

    Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.

  • 储存条件

    · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
    · 3 months, -20 to -80℃ under sterile conditions after reconstitution.
    · 1 week, 2 to 8℃ under sterile conditions after reconstitution.
    · Please avoid repeated freeze-thaw cycles.

  • 文献引用

    1. María Josefina Quezada, Pablo Lopez-Bergami. (2023). The signaling pathways activated by ROR1 in cancer. Cell Signal. 104:110588.

  • 稀释度

背景介绍

  • The receptor tyrosine kinase orphan receptor 1 (ROR1) is a receptor for WNT5A and related Wnt proteins, that play an important role during embryonic development by regulating cell migration, cell polarity, neural patterning, and organogenesis. ROR1 exerts these functions by transducing signals from the Wnt secreted glycoproteins to the intracellular Wnt/PCP and Wnt/Ca++ pathways. Investigations in adult human cells, particularly cancer cells, have demonstrated that besides these two pathways, the WNT5A/ROR1 axis can activate a number of signaling pathways, including the PI3K/AKT, MAPK, NF-κB, STAT3, and Hippo pathways. Moreover, ROR1 is aberrantly expressed in cancer and was associated with tumor progression and poor survival by promoting cell proliferation, survival, invasion, epithelial to mesenchymal transition, and metastasis. Consequently, numerous therapeutic tools to target ROR1 are currently being evaluated in cancer patients.

  • 电泳JSON

    • 1μg (R: reducing condition, N: non-reducing condition).

  • ELISA

    • Immobilized Anti-Human ROR1 Monoclonal Antibody (Zilovertamab) at 2.0μg/mL (100μL/well) can bind Biotinylated ROR1 Fc&Avi Tag, Human(Cat. No. UA010830)with EC50 of 6.61-8.99ng/mL.